These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22250612)

  • 1. Hyperprolactinemia induced by low-dosage amisulpride in Korean psychiatric patients.
    Lee BH; Kang SG; Kim TW; Lee HJ; Yoon HK; Park YM
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):69-73. PubMed ID: 22250612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
    Paparrigopoulos T; Liappas J; Tzavellas E; Mourikis I; Soldatos C
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):92-6. PubMed ID: 16938372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose amisulpride and elevation in serum prolactin.
    Andrade C
    J Clin Psychiatry; 2013 Jun; 74(6):e558-60. PubMed ID: 23842026
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperprolactinemia after low dose of amisulpride.
    Kopecek M; Bares M; Svarc J; Dockery C; Horácek J
    Neuro Endocrinol Lett; 2004 Dec; 25(6):419-22. PubMed ID: 15665803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
    Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
    Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the amisulpride isomers on rat prolactinemia.
    Marchese G; Ruiu S; Casti P; Saba P; Gessa GL; Pani L
    Eur J Pharmacol; 2002 Jul; 448(2-3):263-6. PubMed ID: 12144950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect.
    Marchese G; Ruiu S; Casti P; Bartholini F; Saba P; Gessa GL; Pani L
    Eur J Pharmacol; 2002 Jun; 447(1):109-14. PubMed ID: 12106810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amisulpride: a review of its use in the management of schizophrenia.
    McKeage K; Plosker GL
    CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
    Bliesener N; Yokusoglu H; Quednow BB; Klingmüller D; Kühn KU
    Pharmacopsychiatry; 2004 Jul; 37(4):189-91. PubMed ID: 15467977
    [No Abstract]   [Full Text] [Related]  

  • 13. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D
    Düring SW; Nielsen MØ; Bak N; Glenthøj BY; Ebdrup BH
    Psychiatry Res; 2019 Apr; 274():58-65. PubMed ID: 30780063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
    Tschoner A; Engl J; Rettenbacher MA; Kaser S; Ott HW; Fleischhacker WW; Patsch JR; Ebenbichler CF
    J Clin Psychiatry; 2009 Feb; 70(2):293-4. PubMed ID: 19265646
    [No Abstract]   [Full Text] [Related]  

  • 15. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
    Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
    Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole.
    Paulzen M; Gründer G
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):149-51. PubMed ID: 16942633
    [No Abstract]   [Full Text] [Related]  

  • 18. [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
    Fric M; Laux G
    Psychiatr Prax; 2003 May; 30 Suppl 2():S97-101. PubMed ID: 14509051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers.
    Wetzel H; Wiesner J; Hiemke C; Benkert O
    J Psychiatr Res; 1994; 28(5):461-73. PubMed ID: 7897617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.